Connecting Impaired Fibrinolysis and Dyslipidemia

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 May 6

PMID 38706781

Authors

Maya Rodriguez

Ze Zheng

Affiliations

Soon will be listed here.

Abstract

A State of the Art lecture entitled "Connecting Fibrinolysis and Dyslipidemia" was presented at the International Society on Thrombosis and Haemostasis Congress 2023. Hemostasis balances the consequences of blood clotting and bleeding. This balance relies on the proper formation of blood clots, as well as the breakdown of blood clots. The primary mechanism that breaks down blood clots is fibrinolysis, where the fibrin net becomes lysed and the blood clot dissolves. Dyslipidemia is a condition where blood lipid and lipoprotein levels are abnormal. Here, we review studies that observed connections between impaired fibrinolysis and dyslipidemia. We also summarize the different correlations between thrombosis and dyslipidemia in different racial and ethnic groups. Finally, we summarize relevant and new findings on this topic presented during the 2023 International Society on Thrombosis and Haemostasis Congress. More studies are needed to investigate the mechanistic connections between impaired fibrinolysis and dyslipidemia and whether these mechanisms differ in racially and ethnically diverse populations.

Citing Articles

Visceral Adipose Tissue Inflammation and Vascular Complications in a Rat Model with Severe Dyslipidemia: Sex Differences and PAI-1 Tissue Involvement.

Markova I, Huttl M, Gayova N, Miklankova D, Cerna K, Kavanova M Biomolecules. 2025; 15(1).

PMID: 39858414 PMC: 11763299. DOI: 10.3390/biom15010019.

References

Rojas-Murillo J, Simental-Mendia M, Moncada-Saucedo N, Delgado-Gonzalez P, Islas J, Roacho-Perez J . Physical, Mechanical, and Biological Properties of Fibrin Scaffolds for Cartilage Repair. Int J Mol Sci. 2022; 23(17). PMC: 9456199. DOI: 10.3390/ijms23179879. View

Willnow T, Armstrong S, Hammer R, Herz J . Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995; 92(10):4537-41. PMC: 41979. DOI: 10.1073/pnas.92.10.4537. View

Irigoyen J, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y . The plasminogen activator system: biology and regulation. Cell Mol Life Sci. 2001; 56(1-2):104-32. PMC: 11146966. DOI: 10.1007/pl00000615. View

Plug T, Meijers J . Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2016; 14(4):633-44. DOI: 10.1111/jth.13261. View

Au D, Strickland D, Muratoglu S . The LDL Receptor-Related Protein 1: At the Crossroads of Lipoprotein Metabolism and Insulin Signaling. J Diabetes Res. 2017; 2017:8356537. PMC: 5444004. DOI: 10.1155/2017/8356537. View

Beisiegel U, Weber W . Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A. 1991; 88(19):8342-6. PMC: 52504. DOI: 10.1073/pnas.88.19.8342. View

Xia J, May L, Koschinsky M . Characterization of the basis of lipoprotein [a] lysine-binding heterogeneity. J Lipid Res. 2000; 41(10):1578-84. View

Lugano R, Pena E, Casani L, Badimon L, Padro T . UPA promotes lipid-loaded vascular smooth muscle cell migration through LRP-1. Cardiovasc Res. 2013; 100(2):262-71. DOI: 10.1093/cvr/cvt171. View

Feingold K, Marshall M, Gulli R, MOSER A, Grunfeld C . Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994; 14(11):1866-72. DOI: 10.1161/01.atv.14.11.1866. View

10.

Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L . Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992; 12(1):19-27. DOI: 10.1161/01.atv.12.1.19. View

11.

Actis Dato V, Chiabrando G . The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation. Int J Mol Sci. 2018; 19(6). PMC: 6032055. DOI: 10.3390/ijms19061780. View

12.

Levine J, Oleaga C, Eren M, Amaral A, Shang M, Lux E . Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021; 11(1):430. PMC: 7801442. DOI: 10.1038/s41598-020-79948-x. View

13.

Fredenburgh J, Nesheim M . Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro. J Biol Chem. 1992; 267(36):26150-6. View

14.

Malyszko J, Malyszko J, Hryszko T, Mysliwiec M . Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. Transplant Proc. 2003; 35(6):2219-21. DOI: 10.1016/s0041-1345(03)00756-5. View

15.

Cucuianu M, Knauer O, Roman S . Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states. Thromb Haemost. 1991; 66(5):586-91. View

16.

Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M . Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest. 1978; 61(5):1186-95. PMC: 372639. DOI: 10.1172/JCI109034. View

17.

Rodriguez M, Dai W, Lund H, Osinski K, Zhang Z, Silverstein R . The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-19. Best Pract Res Clin Haematol. 2022; 35(3):101386. PMC: 9527214. DOI: 10.1016/j.beha.2022.101386. View

18.

Mead J, Irvine S, Ramji D . Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002; 80(12):753-69. DOI: 10.1007/s00109-002-0384-9. View

19.

Fogelstrand P, Boren J . Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutr Metab Cardiovasc Dis. 2011; 22(1):1-7. DOI: 10.1016/j.numecd.2011.09.007. View

20.

Walker J, Nesheim M . The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem. 1999; 274(8):5201-12. DOI: 10.1074/jbc.274.8.5201. View